Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. In this case report, we provide evidence of a novel ALK fusion, XPO1-ALK (intergenic), identified by next-generation DNA sequencing in a patient with...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Zhang, Ke-jie Li, Can Wang, Chang-lin Zou, Meng Su
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
XPO1-ALK
brigatinib
lung adenocarcinoma
targeted therapy
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1503262/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items